David D. Meek
CIK 1555337 · Chief Executive Officer · last filed 2026-06-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.67M
Companies
7
Total Filings
41
Lifetime Open-Market Net
-$696.9K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CGEM | Director | — | $17.21 | — | $0 | 3 | 2026-06-18 |
| QURE | Director | 41,740 | $40.07 | $1.67M | -$220.6K | 16 | 2026-06-12 |
| Fusion Pharmaceuticals Inc. (FUSN) Delisted | Director | — | $21.55 | — | $0 | 2 | 2024-06-04 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | Chief Executive Officer | 151,171 | $58.70 | $8.87M | -$321.3K | 5 | 2023-01-24 |
| Entasis Therapeutics Holdings Inc. (ETTX) Delisted | Director | 0 | $2.19 | $0 | $0 | 6 | 2022-07-11 |
| Baxalta Inc (BXLT) Delisted | EVP and President, Oncology | 52,514 | — | — | $0 | 3 | 2016-03-07 |
| ENDOCYTE INC (ECYT) Delisted | Chief Commercial Officer | 7,500 | — | — | -$155.0K | 4 | 2014-02-10 |
Recent Filings · Page 4 of 5
41 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-06-21 | Entasis Therapeutics Holdings Inc. (ETTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-01-29 | QURE | Grant (A) | +3,230 | $0 | EDGAR |
| 2018-06-18 | QURE | Grant (A) | — | $0 | EDGAR |
| 2016-06-07 | — | Disp (D) | −51,640 | $0 | |
| 2016-03-07 | Baxalta Inc (BXLT) Delisted | Mixed | +27,048 | -$36.5K | EDGAR |
| 2015-09-04 | Baxalta Inc (BXLT) Delisted | Tax (F) | −791 | -$27.7K | EDGAR |
| 2015-07-06 | Baxalta Inc (BXLT) Delisted | Mixed | +25,068 | $0 | EDGAR |
| 2014-02-10 | ENDOCYTE INC (ECYT) Delisted | Grant (A) | +7,500 | $0 | EDGAR |
| 2013-09-16 | ENDOCYTE INC (ECYT) Delisted | Mixed | — | -$67.7K | EDGAR |
| 2013-02-21 | ENDOCYTE INC (ECYT) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.